Heparinex is a biopharmaceutical company focused on the novel recombinant synthesis of compounds for (1) the growing anticoagulation market and associated markets and (2) the dermal filler market.
Heparinex focuses on the recombinant synthesis of compounds for the anticoagulation market and the dermal filler market.
Heparinex was incorporated in 2002 and is based in Oklahoma City, Oklahoma.
Heparinex has applications in dermal filler, pharmaceutical/anticoagulation, bulk manufacturing/fermentation processes, medical device coatings, cosmetics, reconstructive surgery, novel autoimmune/infectious disease/cancer drug discovery, and drug conjugation industries.
Heparinex’s proprietary carbohydrate production platform technologies provide applications for multiple high-yield industries.
Heparinex has received a $1.6 million award from the Economic Development Generating Excellence program (EDGE) program, in Nov 2011.